

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      Art Unit: 1628  
Brinkmann, Volker et al.      Examiner: Kim, Jennifer M  
INTERNATIONAL APPLICATION NO: PCT/EP2004/014436  
FILED: December 17, 2004  
U.S. APPLICATION NO: 10/583106  
35 USC §371 DATE: July 19, 2006  
FOR: Use of Sphingosine-1-phosphate (S1P) Receptor Agonists for the  
Treatment of Brain Degenerative Diseases

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME


Sir:

The Office Action of March 25, 2010 has a shortened statutory time set to expire on June 25, 2010. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-3785

Respectfully submitted,

  
Karen DeBenedictis  
Attorney for Applicant  
Reg. No. 32,977

Date: September 17, 2010